Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11952)	12/1/1997 8:29:00 PM
From: shasta23	Respond to of 32384

Yes finally an up day.I hope for another one tommorrow and that volume picks up a little bit which was so-so today.A close above 13 3/4 or better 14 on good volume would make me feel much better. Maybe we still get a little Christmas present ($17/sh)!! Stefan

To: Andrew H who wrote (11952)	12/1/1997 10:11:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

I think I read on WLA thread GLX's compound is in PII. Seems a bit soon to pull Rez for it if there weren't real concerns. Also on CNBC tonight said Rez did 242mill in its first six months.

To: Andrew H who wrote (11952)	12/2/1997 7:59:00 AM
From: Henry Niman	Respond to of 32384

Andy, One of the analysts also questioned the role of GLX's TZD in their decision to halt the sale of Rezulin. (From GLX thread: "Goldman Sachs' Lachman, though, said Glaxo Wellcome is developing its own glitazone drug, which is entering interim-stage trials and may have played a role in the company's decision. "We wonder what their motivation is with respect to the (suspension)," Lachman said. " Here's a comparison between Rezulin and Takeda's compound (note that patients took 400 mg of Rezulin per day, but Takeda's drug was effective at 30 mg per day): Effects of Thiazolidinediones in Diabetes Mellitus Masashi Kobayashi, MD Clinical trials of the insulin sensitizers, thiazolidinediones, have been conducted in several countries throughout the world. Ciglitazone, the first of the insulin sensitizers, was discovered by Dr Iwatsuka and his associates of Takeda Chemical Industries, Ltd., in Japan in 1979. Ciglitazone was shown to decrease insulin resistance in diabetic animals and to potentiate insulin action in vitro. A clinical trial undertaken in patients with NIDDM had to be discontinued in 1982 because of the development of cataracts in the animals that received long-term ciglitazone. Furthermore, ciglitazone was found to have insufficient potency. At that time, a more potent thiazolidinedione, pioglitazone, was prepared for evaluation by Takeda Chemical Industries. In 1983, Dr Horikoshi and his associates at Sankyo Ltd found that troglitazone was a potent insulin sensitizer; the clinical trial was finished last year in Japan. Clinical trials of both troglitazone and pioglitazone have now been completed in Japan. Troglitazone (200 mg bid) was found to decrease mean fasting glucose levels from 181.8 ñ 29.2 mg/dL to 157.2 ñ 30.6 mg/dL at 8 weeks and glycosylated hemoglobin (HbA1c) from 8.61 ñ 1.51% to 8.09 ñ 1.71% at 12 weeks, whereas placebo did not change these values. When these values were analyzed with respect to body mass index (BMI) and fasting insulin levels, patients with a BMI >24 and a fasting insulin level of 5 æU/mL responded relatively well to troglitazone. However, 28% of the NIDDM patients did not respond to troglitazone; these nonresponders did not show any characteristic clinical features. The combination of troglitazone and a sulfonylurea in patients who failed to respond to a sulfonylurea alone resulted in improved glycemic control in 72% of those patients. Side effects included slightly decreased hematocrit and hemoglobin levels. As for pioglitazone (30 mg/d), the clinical trial showed results similar to those of troglitazone. Side effects of pioglitazone also included a slight decrease in hematocrit and hemoglobin and, rarely, edema. These results suggest that troglitazone and pioglitazone are safe insulin sensitizers even for lean Japanese NIDDM patients.